USNA (Usana Health Sciences) COGS-to-Revenue : 0.21 (As of Mar. 2025)

View and export this data going back to 1993. Start your Free Trial

What is Usana Health Sciences COGS-to-Revenue?

Usana Health Sciences's Cost of Goods Sold for the three months ended in Mar. 2025 was $52.4 Mil. Its Revenue for the three months ended in Mar. 2025 was $249.5 Mil.

Usana Health Sciences's COGS to Revenue for the three months ended in Mar. 2025 was 0.21.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Usana Health Sciences's Gross Margin % for the three months ended in Mar. 2025 was 78.98%.

Usana Health Sciences COGS-to-Revenue Historical Data

The historical data trend for Usana Health Sciences's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Usana Health Sciences COGS-to-Revenue Chart

Usana Health Sciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

0.18

0.19

Usana Health Sciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
COGS-to-Revenue	Get a 7-Day Free Trial															0.19	0.19	0.20	0.18	0.21

Usana Health Sciences COGS-to-Revenue Calculation

Usana Health Sciences's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	161.212	/	854.503
	=	0.19

Usana Health Sciences's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	52.445	/	249.539
	=	0.21

Usana Health Sciences (NYSE:USNA) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Usana Health Sciences's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	52.445 / 249.539
	=	78.98 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Usana Health Sciences COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Usana Health Sciences's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Usana Health Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Usana Health Sciences Inc (NYSE:USNA) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

3838 West Parkway Boulevard, Salt Lake City, UT, USA, 84120

Website

https://www.usana.com

Usana Health Sciences Inc is a direct selling and direct-to-consumer nutrition, personal health and wellness company. It developed and manufactured science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness. The company has two reportable segments: direct selling and Hiya direct-to-consumer. The direct selling segment develops and manufactures high quality, science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness in various geographic markets that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children's health and wellness products in the U.S. Key revenue is generated from Direct selling segment.

Executives

Walter Noot	officer: Chief Information Officer	3838 WEST PARKWAY BLVD, SALT LAKE CITY UT 84120
G Doug Iiekking	officer: VP of Finance	C/O USANA HEALTH SCIENCES INC, 3838 W PARKWAY BLVD, SALT LAKE CITY UT 84120
Gilbert A Fuller	officer: CFO and Executive V.P.	55 WANDERWOOD WAY, SANDY UT 84092
Brent Neidig	officer: CO & Man. Dir. of China	3838 WEST PARKWAY BLVD., WEST VALLEY CITY UT 84120
Joshua Foukas	officer: Chief Legal Officer	3838 WEST PARKWAY BLVD., SALT LAKE CITY X1 84120
John Turman Fleming	director	3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120
David Mulham Mulham	officer: Chief Field Development Office	3838 WEST PARKWAY BLVD, SALT LAKE CITY UT 84120
Jim Brown	officer: Chief Production Officer	3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120
Peggie Pelosi	director	3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84111
Paul A. Jones	officer: CFO	3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120
Myron W Wentz	director	3838 W PARKWAY BLVD, SALT LAKE CITY UT 84120
Daniel A. Macuga	officer: Chief Communications Officer	3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120
Kevin Guest	officer: E.V.P. of Marketing	3838 WEST PARKWAY BLVD, SALT LAKE CITY UT 84120
Robert A Sinnott	officer: Chief Scientific Officer	400 55 WATER STREET, VANCOUVER A1 V6B1A1
Frederic J Winssinger	director	2944 N 44TH STREET, SUITE 250, PHOENIX AZ 85018